# Biohit Oyj

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/biohit).

## Overview

Biohit Oyj is a Finnish biotechnology company that operates on a global scale, focusing on the development of diagnostic products and health-promoting supplements. Established in 1988, the company is headquartered in Helsinki, Finland, with subsidiaries in Italy and the United Kingdom. Biohit's mission, 'Innovating for Health,' drives its commitment to addressing global health challenges through innovative solutions. The company's shares are listed on the NASDAQ OMX Helsinki in the Small Cap Healthcare group.

## Products & services

• Diagnostic tests
• Acetaldehyde-binding products
• Monoclonal antibodies
• GastroPanel diagnostic tool
• Acetium products
• Licensing of intellectual property

- **Diagnostic Tests** (40%) — Includes tests for various health conditions, particularly gastrointestinal issues.
- **Acetaldehyde-binding Products** (25%) — Products designed to bind acetaldehyde, a harmful compound.
- **Monoclonal Antibodies** (15%) — Used in various diagnostic and therapeutic applications.
- **Licensing** (20%) — Licensing of Biohit's intellectual property to other manufacturers.

- Diagnostic tests
- Acetaldehyde-binding products
- Monoclonal antibodies
- GastroPanel diagnostic tool
- Acetium products
- Licensing of intellectual property

## Customers

Biohit's customer base includes healthcare providers, diagnostic laboratories, and pharmaceutical companies. These customers utilize Biohit's products for diagnosing and managing gastrointestinal conditions, among others. The company's licensing agreements allow other manufacturers to produce and sell products based on Biohit's intellectual property. Additionally, Biohit's innovative solutions appeal to healthcare systems facing resource constraints and an aging population.

- **Healthcare Providers** (primary) — Purchase diagnostic tests for patient care.
- **Diagnostic Laboratories** (primary) — Use Biohit's tests for accurate diagnostics.
- **Pharmaceutical Companies** (secondary) — Acquire monoclonal antibodies for research and development.
- **Manufacturers** (secondary) — License Biohit's IP to produce and sell products.

- Healthcare providers seeking diagnostic solutions for gastrointestinal issues
- Diagnostic laboratories requiring reliable testing kits
- Pharmaceutical companies interested in monoclonal antibodies
- Manufacturers licensing Biohit's intellectual property for product development
- Healthcare systems addressing resource constraints and aging populations

## Geography

Biohit operates globally with a significant presence in Europe, Asia, and South America. The company's headquarters are in Helsinki, Finland, with subsidiaries in Italy and the UK. Biohit's products are sold in multiple regions, with Europe and Asia being key markets. The company participates in international health technology exhibitions to expand its market reach.

- Headquartered in Helsinki, Finland
- Subsidiaries in Italy and the UK
- Key markets include Europe and Asia
- 98.5% of revenue comes from exports
- Active participation in international health technology exhibitions

## Strategy

Biohit's strategic priorities focus on addressing global health challenges through innovation and collaboration. The company aims to combine profitable business with scientific advancement, particularly in gastrointestinal health. Biohit is committed to developing premium products and expanding its market presence through strategic partnerships. The company also emphasizes the importance of adapting to regulatory changes to ensure continued product sales.

- **Innovation in Gastrointestinal Health** (medium-term) — To address the increasing prevalence of digestive disorders.
- **Regulatory Adaptation** (short-term) — To comply with new EU IVDR regulations.
- **Market Expansion** (long-term) — To increase global reach and sales.

- Innovating for global health challenges
- Combining profitable business with scientific advancement
- Developing premium gastrointestinal health products
- Expanding market presence through strategic partnerships
- Adapting to regulatory changes for continued product sales

## Risks

Biohit faces several risks, including regulatory compliance challenges and the need for successful product registrations. The company's reliance on key markets like China poses geopolitical risks. Additionally, Biohit's investment portfolio is exposed to market volatility and currency fluctuations. The nature of the biotechnology industry also presents inherent risks related to product development and market acceptance.

- **Regulatory Compliance** [high] — Varied registration processes across markets.
- **Geopolitical Exposure** [critical] — Significant sales in China.
- **Market Volatility** [medium] — Investment portfolio exposed to market changes.

- Regulatory compliance challenges in different markets
- Dependence on successful product registrations
- Geopolitical risks in key markets like China
- Exposure to market volatility and currency fluctuations
- Inherent risks in biotechnology product development

## Accounting

Biohit's accounting practices include specific considerations for revenue recognition and licensing agreements. Revenue from product sales is recognized at a point in time when control transfers to the customer. Licensing agreements are accounted for as separate performance obligations. The company also manages lease accounting under IFRS 16, with assets and liabilities initially measured at present value. Biohit's financial statements are influenced by currency translation adjustments due to its international operations.

- **Revenue Recognition** — high
- **Licensing Agreements** — medium
- **Lease Accounting** — medium

- Revenue recognized when control transfers to customer
- Licensing agreements treated as separate performance obligations
- Lease accounting under IFRS 16 with present value measurement
- Currency translation adjustments due to international operations
- Estimates and provisions for licensing agreement revenues

---

*Last updated: 2026-08-11T04:04:51.240532+00:00*